Vista Pharma Peer Comparison
BSE: 524711
₹6.54
₹0.08
(1.24%)
As on 12-Nov-2026 12:21IST
Market cap
₹41 Cr
Revenue (TTM)
₹4 Cr
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Edit
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
41 | 32,997 | 33,174 | 33,091 | 28,779 |
Revenue (₹ Cr) |
4 | 9,779 | 3,751 | 1,593 | 2,100 |
Net Profit (₹ Cr) |
-11.76 | -270.51 | 405.00 | 438.64 | 324.79 |
Net Margin (%) |
-277.62 | -2.71 | 10.48 | 27.16 | 15.36 |
RoE (%) |
-29.00 | -2.55 | 7.91 | 25.02 | 24.02 |
Price to Earnings |
-- | -- | 80.91 | 75.35 | 88.59 |
Price-To-Book |
1.16 | 4.05 | 6.43 | 17.82 | 20.32 |
Income Statement (₹ Cr)
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Operating Revenue
|
3.88 | 9,778.62 | 3,751.00 | 1,592.52 | 2,100.17 |
|
Total Income
|
4.24 | 9,993.26 | 3,863.00 | 1,615.23 | 2,114.53 |
|
Total Expenditure
|
18.23 | 8,578.44 | 2,984.00 | 969.32 | 1,600.14 |
|
EBITDA
|
-14.35 | 1,200.18 | 767.00 | 623.20 | 500.03 |
|
Depreciation
|
0.76 | 887.82 | 228.00 | 41.96 | 57.00 |
|
EBIT
|
-15.11 | 312.36 | 539.00 | 581.24 | 443.03 |
|
Interest
|
1.24 | 347.94 | 218.00 | 4.21 | 40.83 |
|
Other Income
|
0.36 | 214.64 | 112.00 | 22.71 | 14.37 |
|
Exceptional Items
|
0.00 | -216.88 | 12.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-16.00 | -37.82 | 445.00 | 599.74 | 416.57 |
|
Provision for Tax
|
-4.24 | 232.69 | 40.00 | 161.10 | 91.78 |
|
Profit after Tax
|
-11.76 | -270.51 | 405.00 | 438.64 | 324.79 |
Liabilities (₹ Cr)
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
36.44 | 8,142.24 | 5,158.00 | 1,857.45 | 1,416.33 |
|
Minority Interest
|
0.00 | 0.55 | 5.00 | 0.51 | 0.05 |
|
Non-Current Liabilities
|
2.00 | 5,213.99 | 1,617.00 | 47.15 | 376.76 |
|
Current Liabilities
|
16.65 | 5,158.51 | 1,785.00 | 253.37 | 952.98 |
|
Total Liabilities
|
60.29 | 15,513.53 | 8,100.00 | 1,549.26 | 1,451.43 |
Assets (₹ Cr)
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
37.37 | 10,687.30 | 5,527.00 | 1,132.12 | 798.30 |
|
Current Assets
|
15.36 | 7,253.65 | 2,764.00 | 1,012.00 | 1,747.21 |
|
Total Assets
|
60.29 | 15,513.53 | 8,100.00 | 1,549.26 | 1,451.43 |
|
Total Debt*
|
7.40 | 4,720.27 | 1,859.00 | 8.18 | 393.17 |
|
Net Current Assets
|
-1.28 | 2,095.14 | 979.00 | 758.64 | 794.23 |
|
Contingent Liabilities
|
-- | 99.76 | 770.26 | 15.38 | 12.25 |
Cashflow (₹ Cr)
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-6.98 | 892.30 | -22.00 | 118.34 | 159.18 |
|
Cash Flow from Investing Activities
|
-0.44 | -477.46 | -783.00 | -223.94 | -64.81 |
|
Cash from Financing Activities
|
8.06 | -440.83 | 409.00 | 261.12 | -39.81 |
|
Net Cash Inflow / Outflow
|
0.64 | -25.99 | -396.00 | 155.52 | 54.56 |
Ratios
Profitability Ratios
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-8.54 | 6.61 | 4.07 | 20.14 | 26.97 |
|
ROE (%)
|
-29.00 | -2.55 | 7.91 | 25.02 | 24.02 |
|
ROA (%)
|
-20.38 | -1.56 | 4.65 | 22.40 | 14.30 |
|
EBIT Margin (%)
|
-389.43 | 3.19 | 14.37 | 36.50 | 21.09 |
|
Net Margin (%)
|
-277.62 | -2.71 | 10.48 | 27.16 | 15.36 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-60.40 | 9.43 | 25.70 | 45.18 | 46.25 |
|
EBIT Growth (%)
|
-196.62 | -3.72 | 139.56 | 115.51 | 60.95 |
|
Net Profit Growth (%)
|
-131.35 | -199.34 | 894.12 | 95.80 | 89.41 |
|
EPS Growth (%)
|
-131.35 | -410.28 | 599.72 | 63.29 | 76.32 |
|
Book Value Growth (%)
|
27.38 | 2.28 | 29.77 | 94.96 | 42.49 |
Valuation Ratios
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-3.38 | -157.01 | 82.76 | 73.10 | 87.78 |
|
Price / Book Value
|
1.12 | 4.01 | 6.41 | 17.28 | 20.17 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.00 | 0.06 | 0.09 |
|
EV/EBITDA
|
-3.24 | 30.65 | 45.02 | 51.19 | 56.97 |
|
Market Cap (₹ Cr)
|
66.11 | 29,731.27 | 23,064.69 | 19,988.69 | 0.00 |
Solvency Ratios
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.05 | 0.55 | 0.28 | 0.01 | 0.13 |
|
Short term debt to equity ratio
|
0.11 | 0.12 | 0.11 | 0.00 | 0.54 |
|
Current Ratio
|
0.92 | 1.41 | 1.55 | 3.99 | 1.83 |
|
Quick Ratio
|
0.26 | 0.77 | 1.00 | 2.89 | 1.00 |
|
Interest Coverage
|
-11.86 | 0.89 | 3.04 | 143.52 | 11.20 |
Operating Efficiency Ratios
| Vista Pharma | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
8.17 | 23.05 | 16.85 | 22.50 | 27.51 |
|
Asset Turnover
|
0.07 | 0.56 | 0.43 | 0.81 | 0.92 |
|
Receivable days
|
137.33 | 77.05 | 60.36 | 90.06 | 47.59 |
|
Inventory Days
|
271.84 | 77.13 | 64.42 | 61.02 | 62.58 |
|
Payable days
|
284.27 | 173.49 | 218.94 | 96.06 | 228.78 |
|
Cash Conversion Cycle
|
124.89 | -19.30 | -94.15 | 55.02 | -118.62 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
